oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Meningococcal serogroup Y emergence in Europe High importance in some European regions in 2012
Novartis Vaccines & Diagnost GmbH, Marburg, Germany.
Univ Hosp Infect Dis Dr Fran Mihaljevic, Zagreb, Croatia.
Haemophilus & Meningococcus Reference Lab, Ctr Microbiol, Inst Publ Hlth, Srbija, Serbia.
Region Örebro län.
Vise andre og tillknytning
2014 (engelsk)Inngår i: Human Vaccines & Immunotherapeutics, ISSN 2164-5515, E-ISSN 2164-554X, Vol. 10, nr 6, s. 1725-1728Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Neisseria meningitidis is differentiated into 12 distinct serogroups, of which A, B, C, W, X, and Y are medically most important and represent an important health problem in different parts of the world. The epidemiology of N. meningitidis is unpredictable over time and across geographic regions. Recent epidemiological surveillance has indicated an increase of serogroup Y invasive meningococcal disease in some parts of Europe as shown in the epidemiological data for 2010 and 2011 from various European countries previously published in this journal. 1,2 Here, data from 33 European countries is reported indicating that the emergence of serogroup Y continued in 2012 in various regions of Europe, especially in Scandinavia, while in Eastern and South-Eastern Europe the importance of serogroup Y remained low.

sted, utgiver, år, opplag, sider
Landes Bioscience , 2014. Vol. 10, nr 6, s. 1725-1728
Emneord [en]
epidemiology, Europe, invasive meningococcal disease, serogroup Y, meningococcal vaccines, surveillance
HSV kategori
Identifikatorer
URN: urn:nbn:se:oru:diva-56351DOI: 10.4161/hv.28206ISI: 000342763200042PubMedID: 24608912OAI: oai:DiVA.org:oru-56351DiVA, id: diva2:1081818
Merknad

Funding Agencies:

GlaxoSmithKline

Novartis

Pfizer

Tilgjengelig fra: 2017-03-15 Laget: 2017-03-15 Sist oppdatert: 2018-06-19bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Søk i DiVA

Av forfatter/redaktør
Jacobsson, Susanne
Av organisasjonen
I samme tidsskrift
Human Vaccines & Immunotherapeutics

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 42 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf